Other Consolidated Financial Statement Detail

Supplemental Cash Flow Information

Supplemental disclosure of cash flow information for the years ended December 31, 2012, 2011 and 2010 is as follows:



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Cash paid during the year for:
Interest	$	65.4	$	66.7	$	68.1
Income taxes	$	526.6	$	332.7	$	394.7

Non-cash Investing and Financing Activity

In March 2012, upon completion of our acquisition of Stromedix, we recorded $219.2 million of in-process research and development and $48.2 million of goodwill. In addition, we also recorded a contingent consideration obligation of $122.2 million.

In September 2011, upon completion of our acquisition of the noncontrolling interest in our joint venture investments in Biogen Dompé SRL and Biogen Dompé Switzerland GmbH, we recorded a contingent consideration obligation of $38.8 million.

In connection with the construction of the Cambridge facilities that will be leased by us when the construction is completed, we have recorded an asset along with a corresponding financing obligation on our consolidated balance sheet as of December 31, 2012 and 2011, totaling approximately $86.5 million and $2.2 million, respectively. For additional information related to these transactions, please read Note 12, Property, Plant & Equipment to these consolidated financial statements.

In December 2010, upon completion of our acquisition of BIN, we recorded $110.9 million of in-process research and development and $25.6 million of goodwill. In addition, we also assumed a contingent consideration obligation of $81.2 million and a deferred tax liability of $23.7 million.

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Years Ended December 31,
(In millions)	2012			2011			2010
Interest income	$	29.5		$	19.2		$	22.3
Interest expense	(36.5		)	(33.0		)	(36.1		)
Impairments on investments	(5.5		)	(9.9		)	(19.2		)
Gain (loss) on investments, net	10.6			18.8			14.2
Foreign exchange gains (losses), net	(2.5		)	(6.3		)	(3.5		)
Other, net	3.7			(2.3		)	3.3
Total other income (expense), net	$	(0.7	)	$	(13.5	)	$	(19.0	)

Accrued Expenses and Other

Accrued expenses and other consists of the following:



	As of December 31,
(In millions)	2012		2011
Employee compensation and benefits	$	248.5	$	176.3
Revenue-related rebates	191.0		115.0
Deferred revenue	148.0		69.6
Clinical development expenses	51.6		40.8
Royalties and licensing fees	45.2		47.4
Collaboration expenses	37.4		44.2
Current portion of contingent consideration obligations	22.4		10.8
Other	235.8		173.1
Total accrued expenses and other	$	979.9	$	677.2